Market capitalization | $12.85m |
Enterprise Value | $103.73m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.75 |
P/S ratio (TTM) P/S ratio | 0.22 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -3.76% |
Revenue (TTM) Revenue | $59.13m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast Trinity Biotech Plc Sponsored ADR Class A:
1 Analyst has issued a forecast Trinity Biotech Plc Sponsored ADR Class A:
Sep '24 |
+/-
%
|
||
Revenue | 59 59 |
4%
4%
|
|
Gross Profit | 20 20 |
4%
4%
|
|
EBITDA | -8.55 -8.55 |
46%
46%
|
EBIT (Operating Income) EBIT | -10 -10 |
41%
41%
|
Net Profit | -20 -20 |
29%
29%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. It operates through the Americas and Rest of World geographical segments. The company was founded by Ronan O'Caoimh and Denis R. Burger in June 1992 and is headquartered in Bray, Ireland.
Head office | Ireland |
CEO | John Gillard |
Employees | 380 |
Founded | 1992 |
Website | www.trinitybiotech.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.